Vaborbactam

CHEMBL3317857 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
297.1 g/mol
LogP
Phase
4

Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor that covalently and reversibly binds to serine-beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC) and other class A and C beta-lactamases, restoring the activity of meropenem against carbapenem-resistant organisms. It is used in combination with meropenem (Vabomere) for the treatment of complicated urinary tract infections caused by susceptible gram-negative bacteria. It does not inhibit metallo-beta-lactamases.

分子量

297.1400 g/mol

TPSA

124.00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1

InChI

InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1

Molecular Formula

C12H16BNO5S

HBD / HBA

3 / 6

回転可能結合数

5

重原子数

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor that covalently and reversibly binds to serine-beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC) and other class A and C beta-lactamases, restoring the activity of meropenem against carbapenem-resistant organisms. It is used in combination with meropenem (Vabomere) for the treatment of complicated urinary tract infections caused by susceptible gram-negative bacteria. It does not inhibit metallo-beta-lactamases.

Yes, Vaborbactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3317857. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56649692. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.